Pharma & Biotech Events & Conferences
Refine search
Pharmaceutical
Last week, US pharma giant Pfizer chairman and chief executive Albert Bourla presented at the JP Morgan Healthcare Conference in San Francisco. 24 January 2026
Pharmaceutical
The 44th Annual JP Morgan Healthcare Conference saw a focus on internal pipeline prioritization and bolt-on licensing agreements, with industry experts noting an absence of large biopharmaceutical mergers and acquisitions (M&A) announcements typically expected, says intelligence and productivity platform GlobalData. 22 January 2026
Biotechnology
Samsung Epis Holdings yesterday shared corporate progress and updates at the 44th JP Morgan Healthcare Conference. 15 January 2026
Pharmaceutical
Of the billions that have been made and lost by investors in big pharma in the last two or three years, a significant chunk has involved the two biggest players in the burgeoning obesity field—Eli Lilly and Novo Nordisk. 14 January 2026
Pharmaceutical
Maziar Mike Doustdar, the new president and chief executive of Danish pharma major Novo Nordisk, had the chance to set out his stall during a presentation at the JP Morgan Healthcare Conference on Tuesday. 14 January 2026
Pharmaceutical
US pharma major Merck & Co is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed bump. Speaking at the annual JPM conference, chief executive Rob Davis said the company now sees more than $70 billion in commercial opportunity from new growth drivers by the mid-2030s: up $20 billion from a year earlier. 14 January 2026
Biotechnology
Spanish dermatology specialist Almirall is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing. 14 January 2026
Pharmaceutical
Swiss pharma giant Novartis’ has announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali (ribociclib) plus endocrine therapy (ET). 10 December 2025
Biotechnology
Roche has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ambition to move its CD20xCD3 bispecific earlier in follicular and large B-cell lymphomas. 9 December 2025
Pharmaceutical
Italian pharma major Recordati’s rare diseases subsidiary announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be potentially life-threatening. In a series of poster presentations at the 67th American Society of Hematology Annual Meeting (ASH) Annual Meeting in Orlando, Florida. 9 December 2025
Biotechnology
Danish biotech Genmab has announced primary data from the pivotal Phase III EPCORE FL-1 study of fixed duration Epkinly (epcoritamab-bysp) alongside rituximab and lenalidomide (Epkinly + R2) in adults with relapsed or refractory (R/R) follicular lymphoma (FL). 8 December 2025
Pharmaceutical
Belgium’s UCB has presented positive efficacy and safety results from the GEMZ Phase III study investigating adjunctive Fintepla (fenfluramine) in children and adults with CDKL5 deficiency disorder (CDD) at the American Epilepsy Society (AES) meeting, Atlanta, USA. 8 December 2025
Biotechnology
German biotech BioNTech and USA-based OncoC4 yesterday presented data from the non-pivotal dose-confirmation stage of the global randomized Phase III trial PRESERVE-003 for gotistobart (also known as BNT316 or ONC-392), a tumor microenvironment-selective regulatory T cell (Treg) depletion candidate, targeting CTLA-4 in patients with metastatic squamous non-small cell lung cancer (sqNSCLC). 8 December 2025
Biotechnology
US pharma giant Pfizer presented results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 8 December 2025
Biotechnology
Denmark-based clinical-stage techbio Evaxion, which is specializing in developing AI-Immunology powered vaccines, announced new data demonstrating that its AML vaccine candidate, EVX-04, triggers strong specific T-cell responses and effectively prevents tumor growth in pre-clinical models. 8 December 2025
Biotechnology
US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). 6 December 2025
Biotechnology
Japanese drugmaker Eisai and US biotech Biogen announced new data confirming the pharmacological effect of Leqembi (lecanemab) were presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. 3 December 2025
Pharmaceutical
US obesity drug developer Metsera presented detailed results from two Phase IIb trials for its weight-loss drug candidate, MET-097i, at ObesityWeek 2025. 10 November 2025
Biotechnology
Japanese drug major Takeda Friday announced new interim data from the Phase Ib, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. 10 November 2025
Pharmaceutical
German pharma major Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that Kerendia (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of care (95% CI=0.75 [0.65; 0.87]; p=0.0001). 7 November 2025
Pharmaceutical
Last week, US pharma giant Pfizer chairman and chief executive Albert Bourla presented at the JP Morgan Healthcare Conference in San Francisco. 24 January 2026
Pharmaceutical
The 44th Annual JP Morgan Healthcare Conference saw a focus on internal pipeline prioritization and bolt-on licensing agreements, with industry experts noting an absence of large biopharmaceutical mergers and acquisitions (M&A) announcements typically expected, says intelligence and productivity platform GlobalData. 22 January 2026
Biotechnology
Samsung Epis Holdings yesterday shared corporate progress and updates at the 44th JP Morgan Healthcare Conference. 15 January 2026
Pharmaceutical
Of the billions that have been made and lost by investors in big pharma in the last two or three years, a significant chunk has involved the two biggest players in the burgeoning obesity field—Eli Lilly and Novo Nordisk. 14 January 2026
Pharmaceutical
Maziar Mike Doustdar, the new president and chief executive of Danish pharma major Novo Nordisk, had the chance to set out his stall during a presentation at the JP Morgan Healthcare Conference on Tuesday. 14 January 2026
Pharmaceutical
US pharma major Merck & Co is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed bump. Speaking at the annual JPM conference, chief executive Rob Davis said the company now sees more than $70 billion in commercial opportunity from new growth drivers by the mid-2030s: up $20 billion from a year earlier. 14 January 2026
Biotechnology
Spanish dermatology specialist Almirall is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing. 14 January 2026
Pharmaceutical
Swiss pharma giant Novartis’ has announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali (ribociclib) plus endocrine therapy (ET). 10 December 2025
Biotechnology
Roche has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ambition to move its CD20xCD3 bispecific earlier in follicular and large B-cell lymphomas. 9 December 2025
Pharmaceutical
Italian pharma major Recordati’s rare diseases subsidiary announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be potentially life-threatening. In a series of poster presentations at the 67th American Society of Hematology Annual Meeting (ASH) Annual Meeting in Orlando, Florida. 9 December 2025
Biotechnology
Danish biotech Genmab has announced primary data from the pivotal Phase III EPCORE FL-1 study of fixed duration Epkinly (epcoritamab-bysp) alongside rituximab and lenalidomide (Epkinly + R2) in adults with relapsed or refractory (R/R) follicular lymphoma (FL). 8 December 2025
Pharmaceutical
Belgium’s UCB has presented positive efficacy and safety results from the GEMZ Phase III study investigating adjunctive Fintepla (fenfluramine) in children and adults with CDKL5 deficiency disorder (CDD) at the American Epilepsy Society (AES) meeting, Atlanta, USA. 8 December 2025
Biotechnology
German biotech BioNTech and USA-based OncoC4 yesterday presented data from the non-pivotal dose-confirmation stage of the global randomized Phase III trial PRESERVE-003 for gotistobart (also known as BNT316 or ONC-392), a tumor microenvironment-selective regulatory T cell (Treg) depletion candidate, targeting CTLA-4 in patients with metastatic squamous non-small cell lung cancer (sqNSCLC). 8 December 2025
Biotechnology
US pharma giant Pfizer presented results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 8 December 2025
Biotechnology
Denmark-based clinical-stage techbio Evaxion, which is specializing in developing AI-Immunology powered vaccines, announced new data demonstrating that its AML vaccine candidate, EVX-04, triggers strong specific T-cell responses and effectively prevents tumor growth in pre-clinical models. 8 December 2025
Biotechnology
US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). 6 December 2025
Biotechnology
Japanese drugmaker Eisai and US biotech Biogen announced new data confirming the pharmacological effect of Leqembi (lecanemab) were presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. 3 December 2025
Pharmaceutical
US obesity drug developer Metsera presented detailed results from two Phase IIb trials for its weight-loss drug candidate, MET-097i, at ObesityWeek 2025. 10 November 2025
Biotechnology
Japanese drug major Takeda Friday announced new interim data from the Phase Ib, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. 10 November 2025
Pharmaceutical
German pharma major Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that Kerendia (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of care (95% CI=0.75 [0.65; 0.87]; p=0.0001). 7 November 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze